Antibody-Drug Conjugates in Breast Cancer: Emerging Insights, Clinical Integration, and Toxicity Management

Emerging trials show trastuzumab deruxtecan boosts pCR and disease-free survival in early HER2-positive breast cancer, reshaping neoadjuvant/adjuvant care with ILD monitoring.

Explore risk‑adapted T‑DXd use in early HER2+ breast cancer—who benefits, how to sequence therapy, and ILD monitoring hurdles.

New first-line TDxd plus pertuzumab reshapes HER2+ metastatic care, doubling PFS and sparking debate on maintenance and CNS control.

DB-06 reshapes HER2 testing with ultra-low disease, guiding T-DXd timing and comparing Trop-2 ADC options by toxicity and survival data.

New trials redefine HER2 ultra-low disease, guiding when to use T-DXd vs oral chemo and emerging Trop-2 ADC options.

ASCENT-04 shows SG plus pembrolizumab boosts PFS without extra toxicity in PD-L1+ TNBC, while trials test IO for PD-L1− disease.

How doctors sequence ADCs, pick the best first option, and manage T-DXd ILD, nausea and fatigue in metastatic breast cancer.

Clinicians debate sequencing breast cancer ADCs, weighing back‑to‑back use vs chemo breaks, and managing ILD, nausea, fatigue, cardiotoxicity.